346 related articles for article (PubMed ID: 29272162)
1. Circulating Tumor Cell Number as a Response Measure of Prolonged Survival for Metastatic Castration-Resistant Prostate Cancer: A Comparison With Prostate-Specific Antigen Across Five Randomized Phase III Clinical Trials.
Heller G; McCormack R; Kheoh T; Molina A; Smith MR; Dreicer R; Saad F; de Wit R; Aftab DT; Hirmand M; Limon A; Fizazi K; Fleisher M; de Bono JS; Scher HI
J Clin Oncol; 2018 Feb; 36(6):572-580. PubMed ID: 29272162
[TBL] [Abstract][Full Text] [Related]
2. Circulating tumour cell increase as a biomarker of disease progression in metastatic castration-resistant prostate cancer patients with low baseline CTC counts.
Lorente D; Olmos D; Mateo J; Dolling D; Bianchini D; Seed G; Flohr P; Crespo M; Figueiredo I; Miranda S; Scher HI; Terstappen LWMM; de Bono JS
Ann Oncol; 2018 Jul; 29(7):1554-1560. PubMed ID: 29741566
[TBL] [Abstract][Full Text] [Related]
3. Clinical phenotypes associated with circulating tumor cell enumeration in metastatic castration-resistant prostate cancer.
Bitting RL; Healy P; Halabi S; George DJ; Goodin M; Armstrong AJ
Urol Oncol; 2015 Mar; 33(3):110.e1-9. PubMed ID: 25595577
[TBL] [Abstract][Full Text] [Related]
4. A phase II trial of temsirolimus in men with castration-resistant metastatic prostate cancer.
Armstrong AJ; Shen T; Halabi S; Kemeny G; Bitting RL; Kartcheske P; Embree E; Morris K; Winters C; Jaffe T; Fleming M; George DJ
Clin Genitourin Cancer; 2013 Dec; 11(4):397-406. PubMed ID: 23830964
[TBL] [Abstract][Full Text] [Related]
5. Circulating Tumor Cells as a Marker for Progression-free Survival in Metastatic Castration-naïve Prostate Cancer.
Josefsson A; Linder A; Flondell Site D; Canesin G; Stiehm A; Anand A; Bjartell A; Damber JE; Welén K
Prostate; 2017 Jun; 77(8):849-858. PubMed ID: 28295408
[TBL] [Abstract][Full Text] [Related]
6. The Added Value of Circulating Tumor Cell Enumeration to Standard Markers in Assessing Prognosis in a Metastatic Castration-Resistant Prostate Cancer Population.
Heller G; Fizazi K; McCormack R; Molina A; MacLean D; Webb IJ; Saad F; de Bono JS; Scher HI
Clin Cancer Res; 2017 Apr; 23(8):1967-1973. PubMed ID: 27678453
[No Abstract] [Full Text] [Related]
7. Circulating Tumor Cells as a Biomarker of Survival and Response to Radium-223 Therapy: Experience in a Cohort of Patients With Metastatic Castration-Resistant Prostate Cancer.
Carles J; Castellano D; Méndez-Vidal MJ; Mellado B; Saez MI; González Del Alba A; Perez-Gracia JL; Jimenez J; Suárez C; Sepúlveda JM; Manneh R; Porras I; López C; Morales-Barrera R; Arranz JÁ
Clin Genitourin Cancer; 2018 Dec; 16(6):e1133-e1139. PubMed ID: 30104161
[TBL] [Abstract][Full Text] [Related]
8. Circulating tumor cell biomarker panel as an individual-level surrogate for survival in metastatic castration-resistant prostate cancer.
Scher HI; Heller G; Molina A; Attard G; Danila DC; Jia X; Peng W; Sandhu SK; Olmos D; Riisnaes R; McCormack R; Burzykowski T; Kheoh T; Fleisher M; Buyse M; de Bono JS
J Clin Oncol; 2015 Apr; 33(12):1348-55. PubMed ID: 25800753
[TBL] [Abstract][Full Text] [Related]
9. Baseline Circulating Tumor Cell Count as a Prognostic Marker of PSA Response and Disease Progression in Metastatic Castrate-Sensitive Prostate Cancer (SWOG S1216).
Goldkorn A; Tangen C; Plets M; Morrison GJ; Cunha A; Xu T; Pinski JK; Ingles SA; Triche T; Harzstark AL; Kohli M; MacVicar GR; Vaena DA; Crispino AW; McConkey DJ; Lara PN; Hussain MHA; Quinn DI; Vogelzang NJ; Thompson IM; Agarwal N
Clin Cancer Res; 2021 Apr; 27(7):1967-1973. PubMed ID: 33500355
[TBL] [Abstract][Full Text] [Related]
10. Circulating tumor cells as a biomarker predictive of sensitivity to docetaxel chemotherapy in patients with castration-resistant prostate cancer.
Okegawa T; Itaya N; Hara H; Tambo M; Nutahara K
Anticancer Res; 2014 Nov; 34(11):6705-10. PubMed ID: 25368278
[TBL] [Abstract][Full Text] [Related]
11. Decline in Circulating Tumor Cell Count and Treatment Outcome in Advanced Prostate Cancer.
Lorente D; Olmos D; Mateo J; Bianchini D; Seed G; Fleisher M; Danila DC; Flohr P; Crespo M; Figueiredo I; Miranda S; Baeten K; Molina A; Kheoh T; McCormack R; Terstappen LW; Scher HI; de Bono JS
Eur Urol; 2016 Dec; 70(6):985-992. PubMed ID: 27289566
[TBL] [Abstract][Full Text] [Related]
12. Prospective assessment of AR splice variant and PSMA detection on circulating tumor cells of mCRPC patients: preliminary analysis of patients enrolled in PRIMERA trial (NCT04188275).
Francolini G; Loi M; Salvestrini V; Mangoni M; Detti B; Di Cataldo V; Aquilano M; Pinzani P; Salvianti F; Desideri I; Mariotti M; Garlatti P; Stocchi G; Ciccone LP; Lucidi S; Salvatore G; Sottili M; Meattini I; Livi L
Clin Exp Metastasis; 2021 Oct; 38(5):451-458. PubMed ID: 34410545
[TBL] [Abstract][Full Text] [Related]
13. The Phase 3 COU-AA-302 Study of Abiraterone Acetate Plus Prednisone in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Stratified Analysis Based on Pain, Prostate-specific Antigen, and Gleason Score.
Miller K; Carles J; Gschwend JE; Van Poppel H; Diels J; Brookman-May SD
Eur Urol; 2018 Jul; 74(1):17-23. PubMed ID: 28939004
[TBL] [Abstract][Full Text] [Related]
14. Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial.
Fizazi K; Massard C; Bono P; Jones R; Kataja V; James N; Garcia JA; Protheroe A; Tammela TL; Elliott T; Mattila L; Aspegren J; Vuorela A; Langmuir P; Mustonen M;
Lancet Oncol; 2014 Aug; 15(9):975-85. PubMed ID: 24974051
[TBL] [Abstract][Full Text] [Related]
15. Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase III metastatic castration resistant prostate cancer trial.
Goldkorn A; Ely B; Tangen CM; Tai YC; Xu T; Li H; Twardowski P; Veldhuizen PJ; Agarwal N; Carducci MA; Monk JP; Garzotto M; Mack PC; Lara P; Higano CS; Hussain M; Vogelzang NJ; Thompson IM; Cote RJ; Quinn DI
Int J Cancer; 2015 Apr; 136(8):1856-62. PubMed ID: 25219358
[TBL] [Abstract][Full Text] [Related]
16. Circulating Tumor Cells in a Phase 3 Study of Docetaxel and Prednisone with or without Lenalidomide in Metastatic Castration-resistant Prostate Cancer.
Vogelzang NJ; Fizazi K; Burke JM; De Wit R; Bellmunt J; Hutson TE; Crane E; Berry WR; Doner K; Hainsworth JD; Wiechno PJ; Liu K; Waldman MF; Gandhi A; Barton D; Jungnelius U; Fandi A; Sternberg CN; Petrylak DP
Eur Urol; 2017 Feb; 71(2):168-171. PubMed ID: 27522164
[TBL] [Abstract][Full Text] [Related]
17. Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data.
Scher HI; Jia X; de Bono JS; Fleisher M; Pienta KJ; Raghavan D; Heller G
Lancet Oncol; 2009 Mar; 10(3):233-9. PubMed ID: 19213602
[TBL] [Abstract][Full Text] [Related]
18. Prostate-specific antigen growth rate constant after first-line cytotoxic chemotherapy in metastatic castration-resistant prostate cancer: a monoinstitutional experience.
Colloca G; Venturino A; Addamo G; Ratti R; Coccorullo Z; Caltabiano G; Viale G; Guarneri D
Urol Oncol; 2014 Jan; 32(1):42.e1-5. PubMed ID: 24239469
[TBL] [Abstract][Full Text] [Related]
19. Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: final analysis of a multicentre, open-label, early-access protocol trial.
Sternberg CN; Castellano D; Daugaard G; Géczi L; Hotte SJ; Mainwaring PN; Saad F; Souza C; Tay MH; Garrido JM; Galli L; Londhe A; De Porre P; Goon B; Lee E; McGowan T; Naini V; Todd MB; Molina A; George DJ;
Lancet Oncol; 2014 Oct; 15(11):1263-8. PubMed ID: 25242048
[TBL] [Abstract][Full Text] [Related]
20. Circulating tumor cells versus objective response assessment predicting survival in metastatic castration-resistant prostate cancer patients treated with docetaxel chemotherapy.
Thalgott M; Heck MM; Eiber M; Souvatzoglou M; Hatzichristodoulou G; Kehl V; Krause BJ; Rack B; Retz M; Gschwend JE; Andergassen U; Nawroth R
J Cancer Res Clin Oncol; 2015 Aug; 141(8):1457-64. PubMed ID: 25708944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
